NLS Pharmaceutics Names Prof. Tamir Ben-Hur to NewcelX Scientific Advisory Board
NLS Pharmaceutics Ltd. has appointed Professor Tamir Ben-Hur, a prominent neurologist, to its Scientific Advisory Board for NewcelX. This follows the merger of Kadimastem Ltd.’s stem-cell platforms with NLS Pharmaceutics’ expertise in CNS therapeutics. NewcelX aims to develop innovative cell therapies for neurodegenerative diseases like ALS and diabetes, with Ben-Hur's appointment reinforcing the scientific vision of the new entity.
NewcelX Ltd. has announced that Professor Tamir Ben-Hur, a leading neurologist and expert in neuroimmunology and stem-cell-based regenerative medicine, will join its Scientific Advisory Board. This development follows the unification of Kadimastem Ltd.’s advanced stem-cell platforms and clinical programs with NLS Pharmaceutics Ltd.’s expertise in central nervous system therapeutics, forming the foundation of NewcelX. The company aims to advance transformative cell therapies for neurodegenerative and metabolic diseases, including ALS and diabetes. Professor Ben-Hur’s appointment is seen as a strong endorsement of the combined scientific vision and clinical ambitions of the new entity. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO17614) on November 06, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
